These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Clarkson TB; Meléndez GC; Appt SE Menopause; 2013 Mar; 20(3):342-53. PubMed ID: 23435033 [TBL] [Abstract][Full Text] [Related]
28. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213 [TBL] [Abstract][Full Text] [Related]
29. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Vickers MR; MacLennan AH; Lawton B; Ford D; Martin J; Meredith SK; DeStavola BL; Rose S; Dowell A; Wilkes HC; Darbyshire JH; Meade TW; BMJ; 2007 Aug; 335(7613):239. PubMed ID: 17626056 [TBL] [Abstract][Full Text] [Related]
30. Menopause and stroke and the effects of hormonal therapy. Lobo RA Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669 [TBL] [Abstract][Full Text] [Related]
31. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy]. Burckhardt P Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085 [TBL] [Abstract][Full Text] [Related]
32. [Hormone replacement in postmenopausal women with coronary heart disease. Results and clinical consequences from recent studies]. Schurz RA; Benzer W Wien Klin Wochenschr; 1997; 109 Suppl 2():42-5. PubMed ID: 9340923 [TBL] [Abstract][Full Text] [Related]
33. [Effect of oestro-feminal on lipid metabolism in postmenopausal women]. Bohdanowicz-Pawlak A; Milewicz A; Amałowicz B; Tupikowska G; Bolanowski M Wiad Lek; 1992 Sep; 45(17-18):689-92. PubMed ID: 1295257 [TBL] [Abstract][Full Text] [Related]
34. [Cardiovascular risk and hormone replacement therapy in menopause]. Plu-Bureau G Therapie; 1999; 54(3):375-80. PubMed ID: 10500454 [TBL] [Abstract][Full Text] [Related]
35. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease. Mohandas B; Mehta JL Curr Opin Cardiol; 2007 Sep; 22(5):434-42. PubMed ID: 17762545 [TBL] [Abstract][Full Text] [Related]
36. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. Walsh BW; Schiff I; Rosner B; Greenberg L; Ravnikar V; Sacks FM N Engl J Med; 1991 Oct; 325(17):1196-204. PubMed ID: 1922206 [TBL] [Abstract][Full Text] [Related]
37. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. Bayrak A; Aldemir DA; Bayrak T; Corakçi A; Dursun P Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536 [TBL] [Abstract][Full Text] [Related]
38. [Effect of postmenopausal hormone substitution on the lipid profile and coagulation factors in female smokers]. Tatović-Babić D; Beljić T; Drezgić M; Trpković D; Balint-Perić L; Babić D; Nikolić J Srp Arh Celok Lek; 2002; 130(11-12):371-5. PubMed ID: 12751159 [TBL] [Abstract][Full Text] [Related]
39. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Banks E; Canfell K Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078 [TBL] [Abstract][Full Text] [Related]
40. Carcinoma of the breast and hormone replacement therapy for osteoporosis. Crawshaw A Int J Clin Pract; 2000 Mar; 54(2):99-103. PubMed ID: 10824364 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]